12 May 2025 Date | | - Cons. EPS | - EPS |
12 Feb 2025 Date | | - Cons. EPS | - EPS |
11 Nov 2024 Date | | - Cons. EPS | - EPS |
9 Oct 2024 Date | | - Cons. EPS | - EPS |
7 Oct 2024 Date | | - Cons. EPS | - EPS |
12 May 2025 Date | | - Cons. EPS | - EPS |
12 Feb 2025 Date | | - Cons. EPS | - EPS |
11 Nov 2024 Date | | - Cons. EPS | - EPS |
9 Oct 2024 Date | | - Cons. EPS | - EPS |
7 Oct 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Jeffrey A. Bacha CEO | NASDAQ (CM) Exchange | 49720K101 Cusip |
US Country | 1 Employees | - Last Dividend | 18 Oct 2024 Last Split | 22 Feb 2013 IPO Date |
Kintara Therapeutics, Inc. is a clinical stage drug development company focused on the creation and commercialization of novel anti-cancer therapies. The company is at the forefront of developing two Phase III-ready therapeutics, targeting a range of difficult-to-treat solid tumors and other cancer-related conditions. Originally founded in 2009 as DelMar Pharmaceuticals, Inc., the company underwent a rebranding to Kintara Therapeutics, Inc. in August 2020. Its mission is to address the unmet medical needs of cancer patients, particularly those battling drug-resistant cancers. Headquartered in San Diego, California, Kintara has formed a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd., enabling the manufacture and sale of its leading compound VAL-083 in China.
Kintara Therapeutics, Inc. is dedicated to advancing a portfolio of promising anti-cancer treatments. These include: